BCAL Diagnostics Limited (ASX:BDX) has notified the exchange of the cessation of 1,034,243 unquoted options following their expiry on 17 October 2026 without exercise or conversion, according to an Appendix 3H filing dated 13 November 2026.

Key Points

  • 1,034,243 options under the BDXAG class, with an exercise price of $0.20 and expiry date of 17 October 2026, have ceased.
  • The cessation arose from expiry without exercise or conversion, and no consideration was paid by the entity for the cessation.
  • Following the cessation, the BDXAG option class stands at zero securities on issue.
  • Total quoted ordinary fully paid shares (BDX) on issue are 368,683,291 following the change.

Details of Ceased Securities

According to the filing, the securities that have ceased are classified under ASX code BDXAG, described as options expiring 17 October 2026 with an exercise price of $0.20. The number of securities that ceased is 1,034,243. The reason for cessation is recorded as expiry of an option or other convertible security without exercise or conversion, with the date of cessation recorded as 17 October 2026. The company confirmed that no consideration was paid for the cessation, and no additional information was provided by the entity in relation to the cessation event.

Issued Capital Following the Cessation

Following the cessation, BCAL Diagnostics' issued capital comprises 368,683,291 ordinary fully paid shares quoted on ASX under the code BDX. Among unquoted equity securities, the BDXAG class now shows zero securities on issue. Other unquoted classes remaining on issue include 7,050,250 performance rights (BDXAF), 3,467,353 options expiring 20 November 2029 at an exercise price of $0.0574 (BDXAD), 12,000,000 options expiring 8 October 2027 at an exercise price of $0.25 (BDXAH), and 7,600,000 convertible notes (BDXAI).

Filing and Disclosure Details

The Appendix 3H notification was lodged by BCAL Diagnostics Limited, registered under ABN 51142051223, with ASX issuer code BDX. The announcement date is recorded as 13 November 2026 and is designated as a new announcement. The filing notes that figures presented in the issued capital table are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G, or Appendix 3H forms are concurrently with ASX for processing.